Literature DB >> 7681818

Evaluation of the activity of a number of antimicrobial agents against mycobacteria within mouse macrophages by a radiometric method.

D K Banerjee1, B R Patel.   

Abstract

[3H]-uridine was incorporated by Mycobacterium bovis BCG with increasing intensity as the incubation period was increased. Rifampicin and isoniazid inhibited incorporation of the label rapidly. Similar inhibition was seen with M. tuberculosis H37Rv and several clinical isolates of M. tuberculosis both in axenic medium and inside macrophages. Ofloxacin and ciprofloxacin were both inhibitory but clofazimine was not. The combination of rifampicin with either isoniazid or ethambutol produced enhanced killing, but the combination of ethambutol and isoniazid was not synergic. Mycobacterium avium-intracellulare isolates from AIDS patients were less susceptible to rifampicin and were unaffected by isoniazid, ethambutol, clofazimine, ofloxacin and ciprofloxacin. The results obtained by inhibition of [3H]-uridine incorporation by intracellular mycobacteria correlated with conventional in-vitro MICs and was reproducible and rapid; a definitive result was obtainable within seven days.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681818     DOI: 10.1093/jac/31.2.289

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.

Authors:  Takemasa Takii; Yoshifumi Yamamoto; Taku Chiba; Chiyoji Abe; John T Belisle; Patrick J Brennan; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Intracellular multiplication and toxic destruction of cultured macrophages by Capnocytophaga canimorsus.

Authors:  L J Fischer; R S Weyant; E H White; F D Quinn
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

3.  Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.

Authors:  Matthew Zimmerman; Jodi Lestner; Brendan Prideaux; Paul O'Brien; Isabela Dias-Freedman; Chao Chen; Jillian Dietzold; Isaac Daudelin; Firat Kaya; Landry Blanc; Pei-Yu Chen; Steven Park; Padmini Salgame; Jansy Sarathy; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.